BioLineRx Ltd

BioLineRx Ltd. is a biopharmaceutical company that develops and commercializes therapeutics for oncology and rare diseases. Its pipeline includes GLIX1, an oral small molecule targeting DNA damage response in glioblastoma and other cancers, and APHEXDA (motixafortide), a peptide in Phase 1 for sickle cell disease, Phase 2b for pancreatic cancer, and completed Phase 3 for multiple myeloma. The company also develops BL-5010, a pen-like applicator containing an acidic aqueous solution for non-surgical removal of skin lesions. BioLineRx was incorporated in 2003 and is headquartered in Hevel Modi'in, Israel.